Navigation Links
China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
Date:12/10/2009

1,171,145 9,563,803 Non-controlling interest 4,770,180 4,098,940 Total Stockholders' Equity 20,479,675 17,649,375 Total Liabilities and Stockholders' Equity $38,909,890 $31,547,722 CHINA YONGXIN PHARMACEUTICALS INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME FOR THE THREE-MONTH AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2009 AND 2008 (UNAUDITED) For the Three-Month For the Nine-Month Periods Ended Periods Ended September 30, September 30, 2009 2008 2009 2008 Net Revenues $10,844,786 $15,451,100 $29,199,325 $45,025,197 Cost of Goods Sold (7,685,369) (12,412,576) (21,090,595) (36,602,807) Gross profit 3,159,417 3,038,524 8,108,730 8,422,390 Operating Expenses: Selling expenses 912,094 858,038 2,495,546 2,582,411 General and administrative expenses 2,386,349 369,471 3,908,223 1,482,786 Total operating Expenses 3,298,443 1,227,509 6,403,769 4,065,197 Income (Loss) From Operations (139,026) 1,811,015 1,704,961 4,357,193 Other Income (Expense): Other income 1,112,309 683,618 1,906,864 1,517,758 Other expense (19,981) (42,745) (40,763) (77,651) Interest income (expense) (6,919) (55,845) 1,066 (282,957) Total other income 1,085,409 585,028 1,867,166 1,157,150 Operating Income Before Income Tax and Non controlling Interest 946,383 2,396,043 3,572,127 5,514,343
'/>"/>
SOURCE China Yongxin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 ... 2015" therapeutic market research report of 52 pages ... online business intelligence library. The report ... on the therapeutic development for Visceral Pain, complete ... by drug target, mechanism of action (MoA), route ...
(Date:3/26/2015)... HOUSTON , March 26, 2015  The ... of a study independently conducted by the Department ... Japan have been published. ... compared 5-fluorouracil hepatic arterial infusion as post-operative adjuvant ... colorectal metastasis of the liver. ...
(Date:3/26/2015)... March 26, 2015  OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... clinical developments and announced fourth quarter and year ... Developments and Anticipated Near-term MilestonesCustirsen , ... to negotiate the termination of their collaboration and ... final termination agreement are ongoing. , Two ...
Breaking Medicine Technology:Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8
...  Scientists at The Scripps Research Institute have shown that an ... of cocaine. The findings could lead to human clinical trials ... in case of emergency. Cocaine is involved in more than ... in the United States. The findings, reported recently ...
... FRANCISCO, April 18, 2012 Although adherence to hypertension ... total costs of care are higher for adherent patients ... a new study from pharmacy benefit manager Prime Therapeutics ... Academy of Managed Care Pharmacy (AMCP),s 24th Annual Meeting ...
Cached Medicine Technology:Scripps Research Institute Scientists Develop Antidote for Cocaine Overdose 2Scripps Research Institute Scientists Develop Antidote for Cocaine Overdose 3Scripps Research Institute Scientists Develop Antidote for Cocaine Overdose 4Hypertension Drug Adherence Associated with Fewer Hospitalizations and Lower Medical Costs but Increased Total Care Costs 2
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Pitching speed, ... a history of shoulder and elbow injuries, according to new ... Medicine’s ( AOSSM ) Specialty Day. , “Our findings indicate ... a 20% increase in likelihood of a history of injury, ... with a 12% increase likelihood of a history of injury, ...
(Date:3/28/2015)... 2015 Delaying rotator cuff surgery on ... to research presented today at the American Orthopaedic Society ... “Our study compared results for 170 patients who received ... glenohumeral joint capsule release procedure to relieve stiffness at ... lead author from St. George Hospital in Sydney, Australia. ...
(Date:3/28/2015)... 2015 Andrew Hawley of Vintage Rock Posters ... concert posters. The Who and the Doors played together at ... 1968. According to Hawley, “The Who toured the United States ... college campuses. Perhaps the most famous Who poster was a ... the Doors on August 2, 1968 at the Singer Bowl ...
(Date:3/28/2015)... La Mirada, CA (PRWEB) March 28, 2015 ... with ear, nose and throat disorders, are ... Tinnitus is a common issue which is characterized by ... ears. Affecting 1 in 5 people, tinnitus is a ... or disorder and while it is non-fatal, tinnitus can ...
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s Wellness Celebration ... Conference Center in Chesapeake, Virginia. Each year, ARDX celebrates ... in the Hampton Roads region. The 2015 Women’s History ... Women grow stronger through sharing their stories and learning the ... WWC™ theme is T-talk where we will share a cup ...
Breaking Medicine News(10 mins):Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2
... A new type of diagnostic imaging - which can ... cancerous - could be used to prevent unnecessary surgery ... A study by Belgian researchers, which will be ... Society,s Annual Congress in Amsterdam, found that the new ...
... in moderate quantities can reduce the risk of asthma, according ... today (25 September 2011) at the European Respiratory Society,s Annual ... a week could reduce the risk of developing the condition. ... of 12 and 41 yrs of age. All participants completed ...
... A major UK trial has produced firm evidence that ... with early breast cancer significantly reduces the risk of ... The treatment, known as synchronous chemoradiation, has minimal adverse ... of life. Findings from the SEquencing of ...
... of the care of patients with rectal cancer have ... chemotherapy and radiotherapy between European countries. The European ... the European CanCer Organisation compared the treatment ... Netherlands who were diagnosed with rectal cancer between 2008 ...
... for patients with bone metastases from advanced prostate cancer ... III study of an alpha-pharmaceutical in these patients has ... research reported today (Saturday) at the 2011 European Multidisciplinary ... Parker, Consultant Clinical Oncologist at the Royal Marsden Hospital, ...
... Sept. 23 (HealthDay News) -- People,s bodies build up vitamin ... black men who live in areas of the United States ... deficiency than whites who live in the same places. ... recommendations need to change. "This study shows that across-the-board vitamin ...
Cached Medicine News:Health News:New diagnostic imaging for lung cancer could prevent unnecessary surgery 2Health News:Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence 2Health News:Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence 3Health News:Treatment of rectal cancer varies enormously between different European countries 2Health News:Treatment of rectal cancer varies enormously between different European countries 3Health News:First Phase III trial of an alpha-pharmaceutical 2Health News:First Phase III trial of an alpha-pharmaceutical 3Health News:Many Black Men in Cold Climates Lack Vitamin D 2
... Volks Centralis Direct Laser Lens affords the ... posterior segment of the eye. Utilizing a ... bonded protective glass LaserWindow™ exterior, this special ... other lower profile fundus lenses. Available in ...
... Area Centralis® is excellent for critically ... changes from macular degeneration, retinal vascular ... retinopathy and other retinal conditions. It ... of these conditions providing excellent magnification ...
... The Volk TransEquator is designed for ... diagnosis. Its unique optical design presents a ... an impressive wide-field view of the entire ... superior optics of this lens allows dynamic ...
... This unique 129 diopter contact lens has ... at the slit lamp when traditional non-contact ... views. The Equator Plus delivers an outstanding ... be used with pupils as small as ...
Medicine Products: